New drug duo aims to stop deadly liver bleeding
NCT ID NCT07465471
Summary
This study aims to see if adding a drug called midodrine to the standard drug carvedilol works better than carvedilol alone at preventing early rebleeding in people with liver cirrhosis. It will enroll 210 adults with cirrhosis who have just had a serious variceal bleed. Participants will be randomly assigned to receive one of the two drug regimens and followed for 6 weeks to see which group has fewer rebleeds.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, 110070, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.